Top Fifty PAA Share Holders as at 30 November 2022, page-8

Fair point Jakjazz about the general market conditions affecting small biotechs. However, I do not think this problem is an unusual but is a general one that affects small caps, as the opportunities to stuff around with the minds of shareholders is much greater and cheaper in businesses like this. This was detailed by a senate enquiry you yourself mentioned some months back. I suppose all we can do is bear and grin at these antics while waiting for the big breakthrough announcements, or even look at as an opportunity if to load up some more if we haven;t reached our limits.

@Dryasachip, yep, I've been thinking about Elanco in the same way for a long time,and they have form - you only have to look a couple of years back when a group of investors were threatening a multibillion dollar class action against them for being mislead through some dodgy book keeping. Best to have nothing to do with them.